Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ginsenoside Rg5 in preparation of antidepressant drug

A ginsenoside and anti-depressant technology, applied in the field of biomedicine, can solve the problems of insufficient depression effect, intestinal and liver damage, large toxic and side effects, etc., achieve significant effect, less toxic and side effects, and reduce immobility time.

Inactive Publication Date: 2017-07-07
华瑞(福建)生物科技有限公司
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Most existing antidepressants are effective and non-addictive, but adverse effects are a serious problem
However, almost all antidepressants have adverse reactions, and long-term use will cause certain damage to our intestinal tract, gastrointestinal tract and liver, that is, the side effects are relatively large
[0005] As an improvement, the Chinese patent application publication number CN104644652A discloses 20 (R)-ginsenoside Rg 3 Application and medicine in the preparation of medicines for treating depression, although the medicine reduces the toxic and side effects of medicines for treating depression to a certain extent, but the effect of treating depression is not significant enough

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ginsenoside Rg5 in preparation of antidepressant drug
  • Application of ginsenoside Rg5 in preparation of antidepressant drug
  • Application of ginsenoside Rg5 in preparation of antidepressant drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] A kind of ginsenoside Rg 5 Capsules and preparation method thereof

[0032] A kind of ginsenoside Rg 5 The capsules consist of the following raw materials:

[0033]

[0034] The preparation method of above-mentioned capsule, comprises the following steps:

[0035] 1. Weigh ginsenoside Rg according to the above prescription 5 Powder, microcrystalline cellulose and croscarmellose sodium are mixed through an 80-mesh sieve once, and the mixed powder is poured into a wet granulator;

[0036] 2. Add povidone K30 to 500ml purified water and stir to dissolve completely;

[0037] 3. Slowly pour the binder solution 2 into the wet granulator for wet granulation;

[0038] 4. Spread the prepared granules on a baking tray, put them in an oven, and dry at 50°C for 1 hour;

[0039] 5. Take out the dried granules and mix them with magnesium stearate, and pass through a 20-mesh sieve for granulation;

[0040] 6. Fill the prepared granules in 2# capsules to obtain ginsenoside Rg...

Embodiment 2

[0043] Embodiment 2 mouse forced swimming experiment

[0044] 1 Experimental materials

[0045] The Rg prepared by embodiment 1 5 capsule. 20(R)-Rg prepared by the control example 3 capsule. Fluoxetine hydrochloride capsules (Eli Lilly Suzhou Co., Ltd., specification 20mg / capsule (calculated as fluoxetine), batch number: SS41AC). ICR mice, male, weighing 18-22g. Thermometer, stopwatch, water bath, glass tank, video camera.

[0046] 2 Experimental methods

[0047]2.1 90 normal mice were divided into 6 groups on average, namely blank control group, positive drug fluoxetine hydrochloride group 2.5mg / kg, Rg 5 Capsule 12mg / kg, 6mg / kg dose group and 20(R)-Rg 3 Capsule 12mg / kg, 6mg / kg dose group. The above-mentioned capsules were dissolved in deionized water, and each group was dosed at 0.2ml / 10g body weight. Once a day, continuous administration for 7 days, the blank control group was given deionized water.

[0048] 2.2 All the above groups were administered continuously ...

Embodiment 3

[0057] Embodiment 3 Mouse tail suspension experiment

[0058] 1 Experimental materials

[0059] The Rg prepared by embodiment 1 5 capsule. 20(R)-Rg prepared by the control example 3 capsule. Fluoxetine hydrochloride capsules (Eli Lilly Suzhou Co., Ltd., specification 20mg / capsule (calculated as fluoxetine), batch number: SS41AC). ICR mice, male, weighing 18-22g.

[0060] 2 Experimental methods

[0061] 2.1 Animal grouping and administration method, dose and time are the same as in Example 2.

[0062] 2.2 All the above groups were administered continuously for 7 days, and the experiment was carried out 1 hour after the administration on the seventh day. Fix the tail end of the mouse (2cm away from the tail tip) on the connection line of the 300g tension transducer with adhesive tape, so that it is in an upside-down state, and the head is about 15cm away from the experimental platform. Two animals are tested at the same time each time, and the separated by cardboard. Co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of biological medicines and aims at providing an application of ginsenoside Rg5 in preparation of an antidepressant drug. The antidepressant drug is single-component ginsenoside Rg5 or comprises the ginsenoside Rg5 and pharmaceutically acceptable auxiliary materials, wherein the application dosage of the antidepressant drug is 10-500mg / kg everyday on the basis of the weight of the ginsenoside Rg5; and the administration mode of the antidepressant drug is oral administration, instillation or injection. The ginsenoside Rg5 has the beneficial effects that the ginsenoside Rg5 is significant in treatment effect on a depressive disorder, small in toxic or side effect, and high in security.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to ginsenoside Rg 5 Application in the preparation of antidepressants. Background technique [0002] Depression is a group of mental illnesses characterized by significant and persistent changes in emotion or mood. Clinically, it is characterized by depression, loss of interest, slow thinking, and decreased volitional activity, accompanied by corresponding cognitive and behavioral changes. Changes, may have psychotic symptoms, most patients have a tendency to relapse, some patients may have residual symptoms or become chronic. [0003] According to the findings released by the World Health Organization (WHO), the incidence of depression worldwide is about 3.1%, and it is predicted that depression will become one of the main killers of human health in the 21st century. In recent years, with the development and progress of society and the improvement of people's living standards, the inci...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P25/24
CPCA61K31/704
Inventor 胡堃林广勤崔侠
Owner 华瑞(福建)生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com